The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

On November 19, 2015, a marketing authorization valid through the European Union was issued for carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. In a phase III trial in patients...

全面介紹

Na minha lista:
書目詳細資料
發表在:Oncologist
Main Authors: Tzogani, Kyriaki, Camarero Jiménez, Jorge, Garcia, Isabel, Sancho‐López, Arantxa, Martin, Marc, Moreau, Alexandre, Demolis, Pierre, Salmonson, Tomas, Bergh, Jonas, Laane, Edward, Ludwig, Heinz, Gisselbrecht, Christian, Pignatti, Francesco
格式: Artigo
語言:Inglês
出版: AlphaMed Press 2017
主題:
Regulatory Issues: EMA
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5679835/
https://ncbi.nlm.nih.gov/pubmed/28935772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0184
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍